The ship left Seattle in May and spent 18 days at sea, during which more than 100 crew members contracted COVID-19. Three crew members who already had antibodies to the virus did not get sick.
“A lot of people, when they see this, are like, ‘Oh come on, it could be due to random chance,'” Alexander Greninger, MD, PhD, a virologist at Seattle-based University of Washington, told the Times. However, the likelihood that these results are due to chance is extremely low, he said.
The findings, which have not yet been peer-reviewed, have stirred excitement among the scientific community. While past studies show COVID-19 exposure triggers a robust immune response in most humans, this is the first report to add more information about the amount of antibodies needed to offer protection.
Two of the sailors had only moderate quantities of titers — a measure used to indicate the concentration of antibodies in the blood. The case study suggests that even moderate titers could prevent reinfection in humans facing high exposure to the virus.
To read the full article, click here.
More articles on public health:
Cases fall nationwide for 4th week; Chinese government uninformed of COVID-19’s true dangers for weeks, US finds — 5 updates
32 states where COVID-19 is spreading fastest, slowest: Aug. 20
NYC shares data on 1.4 million antibody tests: 3 takeaways
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
